Skip to content

Tango Therapeutics

US · TNGX #2322 by market cap Listed 1970
21.73 -0.98 -4.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:41

Valuation each multiple against its own 5-year range

P/B ratio 4.41 Expensive vs history 76th percentile
5-year average 3.75 · #370 of 514 in Biotechnology
P/E ratio -18.48 Cheap vs history 14th percentile
5-year average -8.75 · forward -13.85
P/S ratio 80.30 Expensive vs history 98th percentile
5-year average 24.66 · forward 1,276.28 · #283 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Tango Therapeutics (TNGX) 3.68B -15.75 3.76 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value22.92 Economic moatNone UncertaintyHigh

Trading 5.5% below Morningstar's fair value estimate.

Fair value

Tango Therapeutics Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 11% premium over our quantitative fair value estimate of $22.92 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability decreases our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -2.6%, which falls in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 28.3%, a core component of valuation, lies in the bottom 30% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:41:45 · For reference only, not investment advice and not tailored to your situation.

Tango Therapeutics discussion 0 comments

Add a comment